TLR4/MyD88信号通路在卵巢癌紫杉醇化疗抵抗中的研究进展

doi:10.3969/j.issn.2095-378X.2019.01.014

外科研究与新技术 ›› 2019, Vol. 8 ›› Issue (1): 49-53.doi: 10.3969/j.issn.2095-378X.2019.01.014

TLR4/MyD88信号通路在卵巢癌紫杉醇化疗抵抗中的研究进展

王安凤¹, 潘晨², 童晓文¹

1.同济大学附属同济医院妇产科,上海 200065;
2.江苏省人民医院溧阳分院妇产科,溧阳 213300

收稿日期:2018-12-25 出版日期:2019-03-28 发布日期:2019-12-09
通讯作者: 童晓文,电子信箱:xiaowen_tong@hotmail.com.
作者简介:王安凤(1993—),女,硕士研究生,住院医师,从事妇科肿瘤临床工作

Research progress on TLR4/MyD88 signaling pathway in paclitaxel-resistant ovarian carcinoma

WANG Anfeng¹, PAN Chen², TONG Xiaowen¹

1.Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China;
2.Department of Obstetrics and Gynecology, Liyang Branch, Jiangsu People’s Hospital, Liyang 213300, China

Received:2018-12-25 Online:2019-03-28 Published:2019-12-09

摘要/Abstract

摘要： 妇科恶性肿瘤是危害妇女健康的重要疾患之一。卵巢癌作为恶性程度最高、死亡率居第一位的妇科恶性肿瘤,70%-80%的患者在初次就诊时已经是Ⅲ~Ⅳ期,尽管现在治疗方法不断改善,仍有80%的卵巢癌患者在1~2年内复发,国际妇产科联盟(FIGO)临床分期Ⅳ期卵巢癌患者的5年总体生存(OS)率＜5%。有研究显示,作为免疫源性肿瘤的卵巢癌,其一线用药紫杉醇有效率仅为30%。紫杉醇是TOLL样受体4(TLR4)的主要配体之一,TLR4在卵巢组织中均有表达,在恶性肿瘤细胞中的染色强度明显增高,MyD88在卵巢癌组织中的表达率为77.1%,但在正常卵巢上皮组织中却不表达,MyD88的高表达是影响卵巢癌患者无瘤生存期与总生存期的独立预后因素。对MyD88阳性的卵巢上皮癌患者,TLR4/MyD88信号通路激活后,能通过促进各类炎症细胞因子增殖、抑制癌细胞凋亡及抑制免疫功能三个方面导致紫杉醇化疗抵抗和复发,甚至促进癌细胞增殖。

关键词: TLR4/MyD88信号通路, 卵巢癌, 紫杉醇抵抗, 负调控, 免疫抑制

Abstract: Gynecological malignancies are one of the important diseases endangering women's health.Ovarian cancer is the most malignant tumour, ranking first in gynecological malignancy death.About 70%-80% of the patients are diagnosed as stage III-IV at their initial visit.Although the treatment methods are ever improving and updating, 80% of the ovarian cancer patients still have a recurrence within one to two years, and the 5-year total survival rate in patients with stage IV ovarian cancer according to International Federation of Gynecology and Obstetrics (FIGO) staging criteria is less than 5%.Studies have shown that paclitaxel, a first-line treatment for immunogenic ovarian cancer, is only 30% effective.Paclitaxel is one of the main ligands of toll-like receptor 4 (TLR4).TLR4 is expressed in all ovarian tissues, and its staining intensity is significantly increased in malignant tumor cells.MyD88 expression is observed in 77.1% ovarian tissues, but not expressed in normal ovarian epithelial tissues, so the high expression of MyD88 is an independent prognostic factor for tumor-free survival and total survival of ovarian carcinoma patients.In epithelial ovarian carcinoma patients with positive MyD88, the activation of TLR4/MyD88-dependent pathway mediates chemoresistance and tumor progression by inflammatory cytokine stimulation, apoptosis inhibition, and immunosuppression, and even promotes cancer cell growth.

Key words: TLR4/MyD88 signaling pathway, Ovarian cancer, Chemoresistance, Negative regulation, Immunosuppression

中图分类号:

C320.3110

王安凤, 潘晨, 童晓文. TLR4/MyD88信号通路在卵巢癌紫杉醇化疗抵抗中的研究进展[J]. 外科研究与新技术, 2019, 8(1): 49-53.

WANG Anfeng, PAN Chen, TONG Xiaowen. Research progress on TLR4/MyD88 signaling pathway in paclitaxel-resistant ovarian carcinoma[J]. Surgical Research and New Technique, 2019, 8(1): 49-53.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer Statistics, 2017[J].CA Cancer J Clin, 2017,67(1):7-30.
[2] Xu JH, Hu SL, Shen GD, et al.Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy[J].Cancer Cell Int, 2016,16(1):13.
[3] Li Z, Block MS, Vierkant RA, et al.The inflammatory microenvironment in epithelial ovarian cancer:a role for TLR4 and MyD88 and related proteins[J].Tumour Biol, 2016,37(10):13279-13286.
[4] Koti M, Siu A, Clément I, et al.A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer[J].Br J Cancer, 2015,113(12):1746.
[5] Zhu Q, Wu X, Wu Y, et al.Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer[J].Oncol Rep, 2016,36(6):3472-3478.
[6] Wang AC, Ma YB, Wu FX, et al.TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro[J].Oncol Lett, 2014,7(3):871-877.
[7] Hemmi H, Takeuchi O, Kawai T, et al.A Toll-like receptor recognizes bacterial DNA[J].Nature, 2000,408(6813):740-745.
[8] Byrd-Leifer C, Block E, Takeda K, et al.The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol[J].Eur J Immunol, 2001,31(8):2448-2457.
[9] Wu X, Mi Y, Yang H, et al.The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-kappaB pathway[J].Mol Cell Biochem, 2013,380(1-2):249-257.
[10] Lin JY, Hu GB, Yu CH, et al.Molecular cloning and expression studies of the adapter molecule myeloid differentiation factor 88(MyD88) in turbot (Scophthalmus maximus)[J].Dev & Comp Immunol, 2015,52(2):166-171.
[11] 朱熠,黄建鸣,张国楠,等.卵巢上皮性癌组织中TLR4/MyD88信号通路的表达及其与临床预后的关系[J].中华妇产科杂志, 2013,48(9):694-697.
[12] 李淑青,陈亚萍.卵巢癌对顺铂和紫杉醇耐药的分子机制[J].国际妇产科学杂志, 2016,43(2):145-150.
[13] Wang AC, Su QB, Wu FX, et al.Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells[J].Eur J Clin Invest, 2010,39(2):157-164.
[14] Candido J, Hagemann T.Cancer-related inflammation[J].J Clin Immunol, 2013,33(1):S79-S84.
[15] Wang J Q, Jeelall Y S, Ferguson L L, et al.Toll-like receptors and cancer:MYD88 mutation and inflammation.[J].Front Immunol, 2014,5(367):367.
[16] Xie X, Yang M, Ding Y, et al.Microbial infection, inflammation and epithelial ovarian cancer[J].Oncol Lett, 2017,14(2):1911-1919.
[17] Tadie JM, Bae HB, Jiang S, et al.HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4[J].Am J Physiol Lung Cell Mol Physiol, 2013,304(5):L342-L349.
[18] Lin Y, Cui M, Xu T, et al.Silencing of cyclooxygenase-2 inhibits the growth,invasion and migration of ovarian cancer cells[J].Mol Med Rep, 2014,9(6):2499.
[19] Ali-Fehmi R, Morris RT, Bandyopadhyay S, et al.Expression of cyclooxygenase-2 in advancedstage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival[J].Am J Obstet Gynecol, 2005,192(3):819-825.
[20] Athanassiadou P, Grapsa D, Athanassiades P, et al.The prognostic significance of COX-2 and survivin expression in ovarian cancer[J].Pathol Res Pract, 2008,204(4):241-249.
[21] Plewka D, Jakubiecbartnik B, Micha Morek, et al.Survivin in ovary tumors[J].Ginekol Pol, 2015,86(7):525-530.
[22] Li S, Yang Y, Ding Y, et al.Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer[J].Oncol Lett, 2017,14(3):3774-3779.
[23] Florent M, Anna K, Clement F, et al.Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1α-independent translation-mediated mechanism[J].Cell Rep, 2014,6(1):155.
[24] Miyamoto M, Takano M, Iwaya K, et al.X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary[J].Br J Cancer, 2014,110(12):2881-2886.
[25] Chen W, Zeng W, Li X, et al.MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis[J].Pharmacogenomics, 2016,17(3):187-197.
[26] Zhang N, Qiu J, Zheng T, et al.Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway[J].Oncol Rep, 2018,39(3):1034-1042.
[27] 邹冬玲,邹冬玲,王冬,等.髓样分化因子促进卵巢癌细胞耐药性的机制研究[J].第三军医大学学报, 2013,35(19):2041-2045.
[28] 王丹,陈晓,徐葳,等.自分泌IL-6经Ras/MEK/ERK、PI3K/Akt通路促进卵巢癌细胞黏附和侵袭功能的研究[J].免疫学杂志, 2016,32(04):294-298.
[29] Duan S, Ying T, Keng P, et al.IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules[J].Oncotarget, 2015,6(29):27651-27660.
[30] Schwab C L, English D P, Roque D M, et al.Past,present and future targets for immunotherapy in ovarian cancer[J].Immunotherapy, 2014,6(12):1279-1293.
[31] Ying X, Li-Ya Q, Feng Z, et al.MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression[J].Biomed Pharmacother, 2015,71(4):64-69.
[32] Bridget C, Kirsten B M, Kimberly R K, et al.Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome[J].Cancer Immunol Res, 2014,2(4):332-340.
[33] 张国楠,朱熠,黄建鸣.对靶向MyD88、IDO1和AHR为中心的免疫抑制信号通路和卵巢上皮性癌免疫治疗的思考[J].中华妇产科杂志, 2018.53(7):448-451.
[34] Whynott R M, Manahan P, Geisler J P.Vascular endothelial growth factor(VEGF) and cyclooxygenase 2(COX 2) immunostaining in ovarian cancer[J].Eur J Gynaecol Oncol, 2016,37(2):164-166.

TLR4/MyD88信号通路在卵巢癌紫杉醇化疗抵抗中的研究进展

Research progress on TLR4/MyD88 signaling pathway in paclitaxel-resistant ovarian carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	李霞, 童晓文. siRNA干扰技术在耐药性卵巢癌中的研究进展[J]. 外科研究与新技术, 2018, 7(2): 127-131.
[2]	徐梦娇童晓文. 游离DNA异常甲基化在卵巢癌中的研究进展[J]. 外科研究与新技术, 2016, 5(2): 132-135,138.